Kim Hyo-Bin, Kim Chang-Keun, Iijima Koji, Kobayashi Takao, Kita Hirohito
Department of Pediatrics, Asthma & Allergy Center, Inje University Sanggye Paik Hospital, Seoul, Korea.
Department of Immunology, Allergic Diseases Research Laboratory, Mayo Clinic and Foundation, Rochester, MN.
Chest. 2009 Feb;135(2):295-302. doi: 10.1378/chest.08-0962. Epub 2008 Nov 18.
Microarray technology offers a new opportunity to gain insight into global gene and protein expression profiles in asthma. To identify novel factors produced in the asthmatic airway, we analyzed sputum samples by using a membrane-based human cytokine microarray technology in patients with bronchial asthma (BA).
Induced sputum was obtained from 28 BA subjects, 20 nonasthmatic atopic control (AC) subjects, and 38 nonasthmatic nonatopic normal control (NC) subjects. The microarray samples of subjects were randomly selected from nine BA subjects, three AC subjects, and six NC subjects. Sputum supernatants were analyzed using a custom human cytokine array (RayBio Custom Human Cytokine Array; RayBiotech; Norcross, GA) designed to analyze 79 specific cytokines simultaneously. The levels of growth-regulated oncogene (GRO)-alpha, eotaxin-2, and pulmonary and activation-regulated chemokine (PARC)/CCL18 were measured by sandwich enzyme-linked immunosorbent assays (ELISAs), and eosinophil-derived neurotoxin (EDN) was measured by radioimmunoassay.
By microarray, the signal intensities for GRO-alpha, eotaxin-2, and PARC were significantly higher in BA subjects than in AC and NC subjects (p = 0.036, p = 0.042, and p = 0.033, respectively). By ELISA, the sputum PARC protein levels were significantly higher in BA subjects than in AC and NC subjects (p < 0.0001). Furthermore, PARC levels correlated significantly with sputum eosinophil percentages (r = 0.570, p < 0.0001) and the levels of EDN (r = 0.633, p < 0.0001), the regulated upon activation, normal T cell expressed and secreted cytokine (r = 0.440, p < 0.001), interleukin-4 (r = 0.415, p < 0.01), and interferon-gamma (r = 0.491, p < 0.001).
By a nonbiased screening approach, a chemokine, PARC, is elevated in sputum specimens from patients with asthma. PARC may play important roles in development of airway eosinophilic inflammation in asthma.
基因芯片技术为深入了解哮喘中的全球基因和蛋白质表达谱提供了新机会。为了鉴定哮喘气道中产生的新因子,我们使用基于膜的人细胞因子芯片技术对支气管哮喘(BA)患者的痰液样本进行了分析。
从28名BA受试者、20名非哮喘特应性对照(AC)受试者和38名非哮喘非特应性正常对照(NC)受试者中获取诱导痰。受试者的芯片样本从9名BA受试者、3名AC受试者和6名NC受试者中随机选取。使用定制的人细胞因子芯片(RayBio定制人细胞因子芯片;RayBiotech;佐治亚州诺克罗斯)分析痰液上清液,该芯片旨在同时分析79种特定细胞因子。通过夹心酶联免疫吸附测定(ELISA)测量生长调节致癌基因(GRO)-α、嗜酸性粒细胞趋化因子-2和肺及活化调节趋化因子(PARC)/CCL18的水平,通过放射免疫测定测量嗜酸性粒细胞衍生神经毒素(EDN)。
通过基因芯片检测,BA受试者中GRO-α、嗜酸性粒细胞趋化因子-2和PARC的信号强度显著高于AC和NC受试者(分别为p = 0.036、p = 0.042和p = 0.033)。通过ELISA检测,BA受试者痰液中PARC蛋白水平显著高于AC和NC受试者(p < 0.0001)。此外,PARC水平与痰液嗜酸性粒细胞百分比(r = 0.570,p < 0.0001)以及EDN水平(r = 0.633,p < 0.0001)、活化后正常T细胞表达和分泌的细胞因子(r = 0.440,p < 0.001)、白细胞介素-4(r = 0.415,p < 0.01)和干扰素-γ(r = 0.491,p < 0.001)显著相关。
通过无偏倚筛选方法,哮喘患者痰液标本中的一种趋化因子PARC升高。PARC可能在哮喘气道嗜酸性粒细胞炎症的发展中起重要作用。